دورية أكاديمية
Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation
| العنوان: | Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation |
|---|---|
| المؤلفون: | SERVAIS, Sophie, Beguin, Yves, Baron, Frédéric |
| المصدر: | Expert Opinion on Emerging Drugs, 18 (2), 173-192 (2013) |
| بيانات النشر: | Informa Healthcare, 2013. |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | alemtuzumab, anti-thymocyte globulin, chimerism, costimulation, CTLA4, fludarabine, graft failure, graft rejection, hematopoietic cell transplantation, mesenchymal stromal cells, reduced-intensity conditioning, total body irradiation, treosulfan, Human health sciences, Hematology, Sciences de la santé humaine, Hématologie |
| الوصف: | Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the treatment of choice for many patients suffering from hematological malignancies, severe hemoglobinopathies, bone marrow failures or severe primary immunodeficiencies. Graft rejection/failure (GF) is a life-threatening complication following allo-HSCT that is most commonly caused by the reactivityof recipient T cells, natural killer (NK) cells or antibodies against donor grafted hematopoietic cells. The increasing use of allo-HSCT following reduced-intensity conditioning (RIC) and the increasing use of alternative donors (unrelated cord blood and human leukocyte antigen (HLA)-mismatcheddonor) have resulted in higher frequency of GF.Areas covered: This review describes the pathogenesis and current prevention and treatment of GF as well as agents in development for GF prevention or treatment.Expert opinion: The risk of GF may be reduced in the future by optimizing the conditioning regimens and post-grafting immunosuppression, increasing the number of hematopoietic stem cells (HSCs) and/or immune cells transplanted, optimizing HSC homing and better detecting patients at high risk of GF by searching for pre-transplant donor-specific anti-HLA antibodies in patientsgiven grafts from HLA-mismatched donors, or by closely monitoring donor T- and/or NK-cell chimerism after allo-HSCT following RIC. |
| نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501 article |
| اللغة: | English |
| Relation: | urn:issn:1472-8214; urn:issn:1744-7623 |
| DOI: | 10.1517/14728214.2013.798642 |
| URL الوصول: | https://orbi.uliege.be/handle/2268/149105 |
| حقوق: | open access http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess |
| رقم الأكسشن: | edsorb.149105 |
| قاعدة البيانات: | ORBi |
| DOI: | 10.1517/14728214.2013.798642 |
|---|